Full TitlePhase I Study of AVID200 in Patients with Myelofibrosis (Myeloproliferative Neoplasms Research Consortium [MPN-RC] 118) (BRANY)
Myelofibrosis is disease that causes scarring of the bone marrow. The purpose of this study is to assess the safety of an investigational drug called AVID200 in patients with myelofibrosis. AVID200 is thought to work by affecting proteins called TGF-beta receptors, which affect how blood cells grow. It is given intravenously (by vein).
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have grade 2 or greater myelofibrosis.
- Patients should either not be eligible for treatment with ruxolitinib or have experienced myelofibrosis growth despite ruxolitinib.
- At least 2 weeks must pass between the completion of prior myelofibrosis treatments and receipt of AVID200.
- Patients must be able to walk and do routine activities for more than half of their normal waking hours.
- This study is for patients age 18 and older.
For more information about this study and to inquire about eligibility, please contact Dr. Raajit Rampal at 212-639-2194.